Amy Mahan focuses her practice on intellectual property matters in the life sciences, pharmaceutical and biotechnology sectors. She works on a variety of patent infringement litigation cases involving monoclonal antibody biologics, cell-based immunotherapies and small molecule drugs.
Amy also works on transactional IP matters on behalf of life science clients, including the preparation, prosecution and strategic management of complex international patent portfolios; patent and trademark-related opinion work, such as freedom to operate, patentability, invalidity, non-infringement and litigation avoidance analyses; and interpretation and enforcement of licensing and research collaboration agreements.
While in law school, Amy served as the executive editor of the University of Pennsylvania Journal of Business Law, obtained a Certificate in Engineering Entrepreneurship and served on the board of two pro bono projects: Penn Housing Rights Projects and Criminal Records Expungement project. During law school, she also interned at the Wistar Institute and the Penn Center for Innovation helping put together licensing and sponsored research agreements to help commercialize promising biomedical technologies.
Before law school, Amy obtained a PhD in Neuroscience from Emory University. Amy also completed postdoctoral research training at Harvard Medical School. Amy’s research focused on the molecular, genetic, epigenetic and neural circuit mechanisms underlying psychiatric disease through an integration of animal models and human genetic research.
Do not send any information or documents that you want to have treated as secret or confidential. Providing information to McDermott via email links on this website or other introductory email communications will not create an attorney-client relationship; will not preclude McDermott from representing any other person or firm in any matter; and will not obligate McDermott to keep confidential the information you provide. McDermott cannot enter into an attorney-client relationship with you until McDermott has determined that doing so will not create a conflict of interest and until you and McDermott have entered into a written agreement or engagement letter that sets forth the terms of our relationship.